Recombinant vaccines for COVID-19

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,745

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Rothan, H. A., & Byrareddy, S. N. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102433 · Cited by 5,840

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Lam, T. T., Jia, N., Zhang, Y.-W., Shum, M. H.-H., Jiang, J.-F., Zhu, H., Tong, Y., Shi, Y., Ni, X.-B., Liao, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2169-0 · Cited by 1,877

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654

Advances in COVID-19 mRNA vaccine development

Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460

Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach

Choudhary, S., Malik, Y. S., & Tomar, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01664 · Cited by 231

COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence?

Maleki, A., Look-Why, S., Manhapra, A., & Foster, C. S. (2021) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v16i3.9443 · Cited by 92

Tracking the COVID-19 vaccines: The global landscape

Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 82

Combatting Salmonella: a focus on antimicrobial resistance and the need for effective vaccination

Nazir, J., Manzoor, T., Saleem, A., Gani, U., Saleem, S., Khan, S. A., Haq, Z., Jha, P., & Ahmad, S. M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10478-5 · Cited by 69

A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19

Mörz, M. (2022) · Vaccines · doi:10.3390/vaccines10101651 · Cited by 65

Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine

Özdemir, İ. H., Özlek, B., Özen, M. B., Gündüz, R., & Bayturan, Ö. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.04.018 · Cited by 53

Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models

Banihashemi, S. R., Es‐haghi, A., Mehrabadi, M. H. F., Noofeli, M., Mokarram, A. R., Ranjbar, A., Salman, Μ. D., Hajimoradi, M., Razaz, S. H., Taghdiri, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836745 · Cited by 48

Anti-vaccination movements in the world and in Brazil

de Oliveira, I. S., Cardoso, L. S., Ferreira, I. G., Alexandre-Silva, G. M., Jacob, B. D. C. D. S., Cerni, F. A., Monteiro, W. M., Zottich, U., & Pucca, M. B. (2022) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0592-2021 · Cited by 46

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report

Mücke, V. T., Knop, V., Mücke, M. M., Ochsendorf, F. R., & Zeuzem, S. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06655-x · Cited by 41

Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity

Zhou, W., Xu, C., Wang, P., Anashkina, A. A., & Jiang, Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab375 · Cited by 42

A behavioral economics perspective on the COVID-19 vaccine amid public mistrust

Saleska, J. L., & Choi, K. R. (2021) · Translational Behavioral Medicine · doi:10.1093/tbm/ibaa147 · Cited by 36

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

Carascal, M. B., Pavon, R. D. N., & Rivera, W. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878943 · Cited by 37

Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges

Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 36

Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19

Bezbaruah, R., Borah, P., Kakoti, B. B., Al‐Shar’i, N. A., Chandrasekaran, B., Jaradat, D. M. M., Al‐Zeer, M. A., & Abu-Romman, S. M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.635337 · Cited by 31

Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms

Aileni, M., Rohela, G. K., Jogam, P., Soujanya, S., & Zhang, B. (2022) · Cells · doi:10.3390/cells11071182 · Cited by 30

The Breadth of Bacteriophages Contributing to the Development of the Phage-Based Vaccines for COVID-19: An Ideal Platform to Design the Multiplex Vaccine

Haq, I. U., Krukiewicz, K., Yahya, G., Haq, M. U., Maryam, S., Mosbah, R., Saber, S., & Alrouji, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021536 · Cited by 26

Parental awareness and utilization of meningococcal serogroup B vaccines in the United States

Srivastava, A. K., Dempsey, A. F., Galitsky, A., Fahimi, M., & Huang, L. (2020) · BMC Public Health · doi:10.1186/s12889-020-09181-8 · Cited by 25

Therapeutic approaches for SARS-CoV-2 infection

Gupta, A., Pradhan, A., Maurya, V. K., Kumar, S., Theengh, A., Puri, B., & Saxena, S. K. (2021) · Methods · doi:10.1016/j.ymeth.2021.04.026 · Cited by 23

Structural and molecular perspectives of SARS-CoV-2

Kumar, S., & Saxena, S. K. (2021) · Methods · doi:10.1016/j.ymeth.2021.03.007 · Cited by 25

Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

Kyei-Barffour, I., Akwetey, S. A., Aninagyei, E., Ghartey‐Kwansah, G., & Acheampong, D. O. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112282 · Cited by 21

A Review of Different Vaccines and Strategies to Combat COVID-19

Sabitha, S., Shobana, N., Prakash, P., Padmanaban, S., Sathiyasree, M., Saigeetha, S., Chakravarthi, S., Uthaman, S., Park, I., & Samrot, A. V. (2022) · Vaccines · doi:10.3390/vaccines10050737 · Cited by 29

ANCA-Associated Vasculitis May Result as a Complication to Both SARS-CoV-2 Infection and Vaccination

Christodoulou, M., Iatridi, F., Chalkidis, G., Λιούλιος, Γ., Nikolaidou, C. C., Badis, K., Fylaktou, A., Papagianni, A. A., & Stangou, M. J. (2022) · Life · doi:10.3390/life12071072 · Cited by 20

Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress

Kovalenko, A. O., Ryabchevskaya, E. M., Evtushenko, E. A., Nikitin, N. A., & Karpova, O. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021701 · Cited by 21

A novel hybrid SEIQR model incorporating the effect of quarantine and lockdown regulations for COVID-19

Prabakaran, R., Jemimah, S., Rawat, P., Sharma, D., & Gromiha, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-03436-z · Cited by 19

Tracing the origin of Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2): A systematic review and narrative synthesis

Thakur, N. N., Das, S., Kumar, S., Maurya, V. K., Dhama, K., Paweska, J. T., Abdel-Moneim, A. S., Jain, A., Tripathi, A. K., Puri, B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28060 · Cited by 17

Preliminary evidence on the safety profile of BNT162b2 ( Comirnaty ): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

Gringeri, M., Mosini, G., Battini, V., Cammarata, G. A. A. M., Guarnieri, G., Carnovale, C., Clementi, E., & Radice, S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1917236 · Cited by 18

Acquired Thrombotic Thrombocytopenic Purpura Following Inactivated COVID-19 Vaccines: Two Case Reports and a Short Literature Review

Saida, I. B., Maatouk, I., Toumi, R., Bouslama, E., Ismail, H. B., Salem, C. B., & Boussarsar, M. (2022) · Vaccines · doi:10.3390/vaccines10071012 · Cited by 16

Current clinical status of new COVID-19 vaccines and immunotherapy

Nagpal, D., Nagpal, S., Kaushik, D. K., & Kathuria, H. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22661-1 · Cited by 17

Recurrent Multiple Evanescent White Dot Syndrome (MEWDS) Following First Dose and Booster of the mRNA-1273 COVID-19 Vaccine: Case Report and Review of Literature

Soifer, M., Nguyen, N. V., Leite, R., Fernandes, J., & Kodati, S. (2022) · Vaccines · doi:10.3390/vaccines10111776 · Cited by 15

Challenges in Emerging Vaccines and Future Promising Candidates against SARS‐CoV‐2 Variants

Ghildiyal, T., Rai, N., Rawat, J. M., Singh, M., Anand, J., Pant, G., Kumar, G., & Shidiki, A. (2024) · Journal of Immunology Research · doi:10.1155/2024/9125398 · Cited by 16

A global survey in the developmental landscape of possible vaccination strategies for COVID-19

Gasmi, A., Srinath, S., Dadar, M., Pivina, L. M., Menzel, A., Benahmed, A. G., Chirumbolo, S., & Bjørklund, G. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108958 · Cited by 16

Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD

Siram, K., Lathrop, S. K., Abdelwahab, W., Tee, R. D., Davison, C. J., Partlow, H. A., Evans, J. T., & Burkhart, D. J. (2023) · Vaccines · doi:10.3390/vaccines12010021 · Cited by 14

Factors and Determinants for Uptake of COVID-19 Vaccine in a Medical University in Riyadh, Saudi Arabia

Tulaihi, B. A., Alharbi, K. G., Alaboodi, T., Alkanhal, H., Alobaid, M. M., & Aldraimly, M. (2021) · Cureus · doi:10.7759/cureus.17768 · Cited by 13

Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine

Lu, C., Zhang, Y., Liu, X., Hou, F., Cai, R., Yu, Z., Liu, F., Yang, G., Ding, J., Xu, J., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105556 · Cited by 12

Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2

Javadi, M. M., Hosseinzadeh, M. T., Soleimani, N., & Rommasi, F. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105687 · Cited by 13

A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants

Liu, Y., Zhao, D., Wang, Y.-C., Chen, Z., Yang, L., Li, W., Gong, Y., Gan, C., Tang, J., Zhang, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011484 · Cited by 12

Noninfectious Uveitis Risk After COVID-19 Vaccination: A Nationwide Retrospective Cohort Study

Chang, M. S., Kim, H. R., Kim, S., Lee, C. S., Byeon, S. H., Kim, S. S., Lee, S. W., & Kim, Y. J. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.09.015 · Cited by 12

Mass spectrometry study on SARS-CoV-2 recombinant vaccine with comprehensive separation techniques to characterize complex heterogeneity

Wu, G., Du, J., Yu, C., Fu, Z., Zhang, X., Wang, L., & Wang, J. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.342349 · Cited by 10

Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge

Nechooshtan, R., Ehrlich, S., Vitikainen, M., Makovitzki, A., Dor, E., Marcus, H., Hefetz, I., Pitel, S., Wiebe, M. G., Huuskonen, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122119 · Cited by 12

Generation and Characterization of Recombinant Pseudorabies Virus Delivering African Swine Fever Virus CD2v and p54

Wei, J., Liu, C., He, X., Abbas, B., Chen, Q., Li, Z., & Feng, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010335 · Cited by 11

To do or not to do? Technological and social factors affecting vaccine coverage

Orlandi, L. B., Zardini, A., Rossignoli, C., & Ricciardi, F. (2021) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2021.121283 · Cited by 10

Eosinophil‐rich linear IgA bullous dermatosis induced by mRNA COVID ‐19 booster vaccine

Nahm, W. J., Juarez, M. C., Wu, J. H., & Kim, R. H. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14305 · Cited by 10

Emerging Cationic Nanovaccines

Carmona‐Ribeiro, A. M., & Pérez-Betancourt, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111362 · Cited by 8

Immunotherapy for neuroblastoma using mRNA vaccines

Ahmed, T. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100033 · Cited by 8

Recombinant vaccines: Current updates and future prospects

Kumar, V., Verma, A., Singh, R., Garg, P., Sharma, S. K., Singh, H. N., Mishra, S. K., & Kumar, S. (2024) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/apjtm.apjtm_854_23 · Cited by 8

Scope of SARS-CoV-2 variants, mutations, and vaccine technologies

Wambani, J., & OKOTH, P. K. (2022) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-022-00121-z · Cited by 9

Mobile On Demand COVID-19 Vaccine Production Units for Developing Countries

Fahr, S. R., Peña‐Benavides, S. A., Thiel, L., Sengoba, C., Karacasulu, K., Ihling, N., Sosa‐Hernández, J. E., Gilleskie, G. L., Woodley, J. M., Parra‐Saldívar, R., et al. (2022) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.2c01217 · Cited by 8

Knowledge, Attitude, and Acceptance of Sinopharm and AstraZeneca’s COVID-19 Vaccines among Egyptian Population: A Cross-Sectional Study

Boshra, M. S., Elgendy, M. O., Abdelaty, L. N., Tammam, M., Alanazi, A. S., Alzarea, A. I., Alsahali, S. M., & Sarhan, R. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416803 · Cited by 8

An Engineered SARS-CoV-2 S1 Glycoprotein Produced in Pichia pastoris as a Candidate Vaccine Antigen

Majidi, S., Kolyani, K. A., Akrami, M., & Dadar, M. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01409-5 · Cited by 7

SARS-CoV-2 epidemiology, antibody dynamics, and neutralisation capacity in Irish healthcare workers in the era of booster COVID-19 vaccinations

McGrath, J., Kenny, C., Nielsen, C. S., Domegan, L. M., Walsh, C., Rooney, P., Walsh, S., Conlon, N. P., Brady, G., Ibrahim, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1078022 · Cited by 7

Microencapsulation of Probiotics and Its Application as Co-Delivery Systems: Review of Literature

Kiprono, S. J., Wambani, J., Langat, V., Rono, J., & Yang, G. (2024) · ES Food & Agroforestry · doi:10.30919/esfaf1106 · Cited by 8

Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

Homma, T., Nagata, N., Hashimoto, M., Iwata‐Yoshikawa, N., Seki, N. M., Shiwa-Sudo, N., Ainai, A., Dohi, K., Nikaido, E., Mukai, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25418-5 · Cited by 6

Impact of the COVID-19 vaccine booster strategy on vaccine protection: a pilot study of a military hospital in Taiwan

Wang, Y., Cheng, S.-T., Shen, C., Huang, S.-W., & Cheng, C. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.4.337 · Cited by 5

Sinovac vaccination and the course of COVID-19 disease in hospitalized patients in Turkey

Delen, L. A., & Örtekus, M. (2022) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2022.147 · Cited by 5

Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity—lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices

McGrath, J., O’Doherty, L., Conlon, N. P., Dunne, J., Brady, G., Ibrahim, A., McCormack, W. J., Walsh, C., Domegan, L. M., Walsh, S., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1245464 · Cited by 4

Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial

Feng, G., Wang, Z., He, P., Lan, Q.-Y., Ni, L., Yang, Y., Wang, C.-F., Cui, T.-T., Huang, L., Yan, Y.-Q., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2262635 · Cited by 4

Sequelas da Covid-19 e o papel da fisioterapia na reabilitação do paciente

Costa, C. S., Almeida, V. A. L., Oliveira, I. G. B., Oliveira, J. D. C. N. D., Bezerra, E. A. G., Lopes, M. C. S., Pereira, W. V. S., Barbosa, P. G. P., Barbosa, R. D. L., & Júnior, M. A. B. (2022) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e10052.2022 · Cited by 3

Combined prevention and treatment measures are essential to control nosocomial infections during the COVID-19 pandemic

Liu, J., Li, Y., Wang, M., & Yang, J. (2024) · World Journal of Virology · doi:10.5501/wjv.v13.i2.91286 · Cited by 3

A review of SARS-CoV-2 virology, vaccines, variants and their impact on the COVID-19 pandemic

Hirahata, T., Quraish, R. U., Quraish, A. U., & Quraish, S. U. (2024) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000393 · Cited by 4

Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design

Addala, S., Vissapragada, M., Aggunna, M., Mukala, N., Lanka, M., Gampa, S., Sodasani, M., Chintalapati, J., Kamidi, A., Veeranna, R. P., et al. (2022) · Vaccines · doi:10.3390/vaccines10060841 · Cited by 3

COVID-19 Vaccines - Current State and Perspectives

Abdurakhmonov, I. Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101006 · Cited by 4

Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein

Zhou, Y.-F., Nie, J., Shi, C., Ning, K., Cao, Y., Xie, Y., Xiang, H., & Xie, Q. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2205.05023 · Cited by 3

Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries

Aripov, T., Wikler, D. I., Asadov, D. A., Tulekov, Z., Murzabekova, T., & Münir, K. (2022) · BMC Medical Ethics · doi:10.1186/s12910-022-00764-1 · Cited by 2

tANCHOR cell-based ELISA approach as a surrogate for antigen-coated plates to monitor specific IgG directed to the SARS-CoV-2 receptor-binding domain

Bernauer, H. S., Maier, J. M., Bannert, N., & Ivanusic, D. (2024) · Biology Methods and Protocols · doi:10.1093/biomethods/bpae001 · Cited by 2

What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?

Kayali, F., Leung, M. S. T., Wong, W., Morgan, K., & Harky, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2057795 · Cited by 2

Effectiveness and Possible Side effects of the Covishield Vaccine in Preventing Covid-19

Tiwari, P., Tiwari, P., & Patel, P. (2025) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2025.00029 · Cited by 1

Previous and potential mutations of Sars-cov-2 receptors and their interaction with known inhibitors

Oranu, E. C., Ijeawele, A., Egbuna, R. N., Ezeonyi, E. I., Okolo, C. C., & Uzochukwu, I. C. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.24.3.0374 · Cited by 1

COVID-19 Vaccines: An Account of Need and Efficacy vs Safety and Challenges

Nag, A., Kalra, A., Sharma, H., Shringi, H., & Kumar, A. (2021) · LS International Journal of Life Sciences · doi:10.5958/2319-1198.2021.00010.5 · Cited by 1

Adverse Events Following Immunization with SARS-CoV-2 Vaccines and its Reporting in India: A Growing Concern

Sharma, A., Noor, R., & Khan, S. (2022) · Asian Pacific Journal of Health Sciences · doi:10.21276/apjhs.2022.9.1.43 · Cited by 1

Bilateral optic neuritis and myocarditis after the first dose of COVID-19 vaccine

Abusamra, K., Kini, T. A., Sudhakar, P., & Ryan, S. (2022) · Neuroimmunology Reports · doi:10.1016/j.nerep.2022.100139 · Cited by 1

COVID-19 vaccines and homoeopathy – An integrative review

Gilla, D., Sreelakshmy, S. R., & Kumar, B. R. (2022) · Indian Journal of Research in Homoeopathy · doi:10.53945/2320-7094.1022 · Cited by 1

What Pausing the AI Arms Race is and isn't: the Right Side of History or Wishful Thinking

Blumenthal, R. L. (2023) · ACM SIGCAS Computers and Society · doi:10.1145/3625671.3625678 · Cited by 1

A Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO.IL-2Rγc KO. NOD) for COVID-19Preprint

Brumeanu, T., Vir, P., Karim, A. F., Kar, S., Benetiene, D., Lok, M., Greenhouse, J. J., Putman-Taylor, T., Kitajewski, C., Chung, K. K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-225156/v1 · Cited by 1

Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19

Sharma, M., Singh, T. U., Lingaraju, M. C., & Parida, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96899

An overview of COVID-19 vaccine candidates

Kang, J., Peng, S., Zhang, W., & Zuo, Y. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202129203060

COVID-19: Vaccines on Their Marks

Jagtiani, E., & Vithlani, D. (2021) · The Bombay Technologist · doi:10.36664/bt/2021/v68i1/162888

Vaccine Race for COVID-19 Battle

Khanal, D. P. (2021) · Journal of Manmohan Memorial Institute of Health Sciences · doi:10.3126/jmmihs.v7i1.43144

Leucocytoclastic Vasculitis Following Coronavirus Vaccine: A Case Report

Ochi, M. R. E., Bahadi, N., Zaizaa, M., Hallab, I., Allaoui, M., Essaoudi, A., Ktaibi, A. E., Sekkach, Y., Damiri, A., Chahdi, H., et al. (2022) · Saudi Journal of Medical and Pharmaceutical Sciences · doi:10.36348/sjmps.2022.v08i02.007

Detección clínica de COVID 19, influencia psicosocial y vacunas anti-covid en la población riobambeña

Velasco-Muso, M. V., Velasco-Basantes, M. M., Herrera-Méndez, A. M., & Alfonso-González, I. (2022) · Revista Arbitrada Interdisciplinaria de Ciencias de la Salud Salud y Vida · doi:10.35381/s.v.v6i1.1714

The efficacy and safety of COVID-19 vaccine A protocol of systematic review and meta-analysis

Xue, X., Deng, Z., Li, N., Zhou, L., Wang, N., Xu, F., & Wang, X. (2021) · doi:10.37766/inplasy2021.3.0048

Behind the mask

Odetola, F. O. (2022) · Academic Emergency Medicine · doi:10.1111/acem.14548

Analyzing Toxicology Reports of the COVID-19 Vaccine

Lingala, E., Appavu, R., & Kethar, J. (2021) · Journal of Student Research · doi:10.47611/jsrhs.v10i4.1996

Efectividad de las vacunas COVID-19

Castañeda-Rodriguez, K. D. P., Gamboa-Cruzado, J., Montero, J. S. N., Villavicencio, L. I., & Zavala-Gutierrez, A. A. (2022) · Boletín de Malariología y Salud Ambiental · doi:10.52808/bmsa.7e6.624.018

A importância da atuação da fisioterapia na reabilitação de pacientes pós-infecção por COVID-19 em um ambulatório no interior da Amazônia: um relato de experiência

da Silva, B. S., Sousa, F. V. V., Leite, L. A. R., Marinho, D. F., Ribeiro, A. P. L., de Sousa, E. S., dos Reis, J. M. F., da Silva, L. M. S., Vinholte, P. A. D. C., & Paiva, C. E. A. (2022) · Research Society and Development · doi:10.33448/rsd-v11i12.34545

Transmission and intervention dynamics of SARS-CoV-2

Korsah, M. A., Acquah, C., & Danquah, M. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91814-5.00009-x

ZF2001, A Protein Subunit Vaccines against SARS-CoV-2

Chen, F., & Gao, Y. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109170

Research progress of recombinant novel coronavirus protein vaccine

Hokwan, O., & Zhang, X. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v40i.6523

Novel Formulation Approaches for Treatment of Ebola Virus

Bhattacharya, S., Singh, S., Chakraborty, S., Prajapati, B. G., Chougule, M. B., & Patel, J. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-20537-8_7

An Outline of the Immunogenic Potential of Progressing SARSCoV- 2 Vaccine Technologies among Children and Adolescents

Ghanem, H., Ghanem, S., & Almutawa, E. (2023) · Recent Patents on Biotechnology · doi:10.2174/1872208317666230612141930

Covid-19 vaccines and their adequacy prospects in Pakistani population; A comparative review

Awais, M. (2023) · Pure and Applied Biology · doi:10.19045/bspab.2023.120129

Foldon fusion of RBD and S1 fragments of SARS‐CoV‐2 to stabilize the structure of subunit protein as a vaccine candidate

Purwanto, G. C. L., Damai, F. I., Agustiyanti, D. F., Wisnuwardhani, P. H., Fathurahman, A. T., Rubiyana, Y., Ramadani, R. D., Sidqi, M. K. L., Prasetyaningrum, P. W., Septisetyani, E. P., et al. (2023) · Indonesian Journal of Biotechnology · doi:10.22146/ijbiotech.82159

Efficacy of Natural Products against Zoonotic Disorders

(2023) · International Journal of Agriculture and Biosciences · doi:10.47278/book.zoon/2023.041

REVIEW: CHEMICAL BONDS IN MOLECULAR AGGREGATION – FROM DRINKING WATER TO NANOCOMPOSITES

Senna, M. (2024) · Citi Science · doi:10.60167/csj/v4i1.2024.02

Yeast-Produced S1 Recombinant Protein of SARS-CoV-2

Majidi, S., Aghaeipour, K. H., Kiasari, B. A., Akrami, M., Mohammadi, A., Najafi, H., & Mousavi, F. (2022) · Bulletin de la Banque nationale de Perse. · doi:10.61186/vacres.9.2.37

Exploring the promise of COVID-19 vaccines: A review of preclinical studies

Adhikary, S., Buttar, H. S., Tuli, H. S., & Kaur, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00052-4

TBHEB 2024-2 Vol 81 Full Printed Journal

ERCÖMERT, U. (2024) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2024.17999

COVID-19 vaccine hesitancy in Türkiye: An infodemiological study

Avcı, K. (2024) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2024.34079

Novel Design for Multi-Epitope Vaccines of COVID-19 and Critical In silico Assessment Steps

Lan, T., Su, S., Ping, P., & Li, J. (2024) · Current Bioinformatics · doi:10.2174/0115748936303461240827061629

Analyzing Toxicology Reports of the COVID-19 Vaccine

Lingala, E., Appavu, R., & Kethar, J. (2021) · Journal of Student Research · doi:10.47611/jsrhs.v10i4.1996

COVID-19: An Update on Vaccine Development

Tripathi, D., Yi, G., & Vankayalapati, R. (2020) · Indian Journal of Rheumatology · doi:10.4103/0973-3698.285394 · Cited by 6

SARS-CoV-2 Recombinant of Drug

Ranjani, P., Govindaraju, A., Manikandan, D., & Riyaz, S. U. M. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815050325122010013

SARS-CoV-2 evolution and vaccines: cause for concern?

Williams, T., & Burgers, W. A. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00075-8 · Cited by 163

SARS-CoV-2 Targets and COVID-19 Vaccines

Currier, A. W., Jeshurin, M. C., & Sampson, V. B. (2021) · COVID · doi:10.3390/covid1030051 · Cited by 10